Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10205026 | 1.00 | ACHE (0.39) | ACHEMGLLRECQLCYP2C9TSHR | |
| SCHEMBL13671265 | 0.88 | PHGDH (0.31) | — | |
| SCHEMBL8259406 | 0.88 | PHGDH (0.31) | — | |
| SCHEMBL13671266 | 0.88 | PHGDH (0.31) | — | |
| SCHEMBL23692028 | 0.83 | ACHE (0.32) | ACHEMGLL | |
| SCHEMBL19766553 | 0.79 | POLB (0.35) | ACHEMGLLRECQL | |
| SCHEMBL21214207 | 0.75 | — | — | |
| SCHEMBL14410771 | 0.73 | MAPK1 (0.33) | — | |
| SCHEMBL17465663 | 0.73 | KDM4E (0.31) | TDP1ALDH1A1 | |
| SCHEMBL18884046 | 0.71 | MAPK1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20220315568-A1 | INHIBITORS OF SARM1 | DISARM THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
| US-11028064-B2 | Tricyclic heterocyclic derivatives and uses thereof | AUCKLAND UNISERVICES LIMITED (NZ) | 2021-06-08 | — | — | US | disclosed |
| US-20190276423-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES AND USES THEREOF | AUCKLAND UNISERVICES LIMITED (NZ) | 2019-09-12 | — | — | US | disclosed |
| US-20160009733-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | UNIVERSITY OF WOLLONGONG (AU) | 2016-01-14 | — | — | US | disclosed |
| US-9156855-B2 | Regulation of nitric oxide release and biofilm development | Newsouth Innovation Pty Limited (AU) | 2015-10-13 | — | — | US | disclosed |
| US-20140221331-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | UNIVERSITY OF WOLLONGONG (AU) | 2014-08-07 | — | — | US | disclosed |
| US-20120094986-A1 | ANTICANCER DERIVIATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-04-19 | — | — | US | disclosed |
| US-20120053209-A1 | ANTICANCER COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053170-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | SANOFI (FR) | 2012-03-01 | — | — | US | disclosed |
| US-20100093723-A1 | HETEROCYCLYL AND CYCLOALKYL SUBSTITUTED THIENO[2,3 d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | ACHE 4819/4885MGLL 4839/4885RECQL 287/4885 |
| US-11028064-B2 | Tricyclic heterocyclic derivatives and uses thereof | CSF3R, CSF1R, FLT3 | ACHE 1753/4885MGLL 3298/4885RECQL 3183/4885 |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | ACHE 4326/4885MGLL 4480/4885RECQL 122/4885 |
| US-20120053170-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | NAMPT, NNT, NQO1 | ACHE 3042/4885MGLL 2998/4885RECQL 842/4885 |
| US-20120094986-A1 | ANTICANCER DERIVIATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | NAMPT, NQO1, NNT | ACHE 3429/4885MGLL 4048/4885RECQL 1423/4885 |
| US-20160009733-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | NOS1, NOS2, NOS3 | ACHE 3009/4885MGLL 812/4885RECQL 4484/4885 |
| US-20100093723-A1 | HETEROCYCLYL AND CYCLOALKYL SUBSTITUTED THIENO[2,3 d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | ADORA2A, ADORA3, ADORA2B | ACHE 780/4885MGLL 4523/4885RECQL 452/4885 |
| US-20190276423-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES AND USES THEREOF | CSF3R, CSF1R, FLT3 | ACHE 1753/4885MGLL 3298/4885RECQL 3183/4885 |
| US-20220315568-A1 | INHIBITORS OF SARM1 | SARM1, SMN1; SMN2, SARNP | ACHE 3185/4885MGLL 3429/4885RECQL 3312/4885 |
| US-20140221331-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | NOS1, NOS2, NOS3 | ACHE 3009/4885MGLL 812/4885RECQL 4484/4885 |
| US-20120053209-A1 | ANTICANCER COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | NAMPT, NQO1, NADK | ACHE 3699/4885MGLL 2966/4885RECQL 1309/4885 |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | ACHE 4711/4885MGLL 3247/4885RECQL 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.